Healthcare Providers and Services
Company Overview of Castle Biosciences Incorporated
Castle Biosciences Incorporated develops and commercializes diagnostic and prognostic tests for cancers. It offers DecisionDx-Melanoma, a gene expression profile test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue; DecisionDx-UM test, a highly accurate prognostic tool to measure the activity or gene expression of a set of 15 genes within an ocular melanoma tumor to identify the likelihood of metastasis; and a multivariate diagnostic test that determines the molecular signature of a glioblastoma multiforme tumor. The company also provides development programs for assays in esophageal cancer, eye cancer, me...
820 South Friendswood Drive
Friendswood, TX 77546
Founded in 2007
Key Executives for Castle Biosciences Incorporated
Founder, Chief Executive Officer, Presiden, and Director
Vice President of Operations
Compensation as of Fiscal Year 2016.
Castle Biosciences Incorporated Key Developments
Castle Biosciences, Inc. Announces Clinical Results of Melanoma Gene Expression Test in Stage I and II Cohort Study
Jul 28 16
Castle Biosciences Inc. announced the results from a study evaluating the performance of its gene expression profile (GEP) test DecisionDx-Melanoma in a cohort of 356 Stage I and II melanoma patients. The data confirm findings from two previously published multicenter clinical validation studies and further support the test’s ability to identify patients’ risk of melanoma recurrence in the five years following diagnosis. Results from the study, led by Dr. Laura Ferris, are being presented in a poster at the 2016 American Academy of Dermatology (AAD) Summer Meeting. Performance of a Prognostic 31-Gene Expression Profile test to Identify High Risk Stage I and II Melanoma Patients (Abstract # 4067), 356 Stage I and II cutaneous melanoma tumors from 12 centers in the U.S. were analyzed in a CAP/CLIA-accredited laboratory using the DecisionDx-Melanoma test and classified as either low risk Class 1 or high risk Class 2. Study endpoints included recurrence-free survival (RFS), defined as time to either a regional or distant metastatic event, distant metastasis-free survival (DMFS), defined as time to any metastatic event beyond the regional node, and metastasis-free survival (MSS), defined as time from diagnosis to death documented as specifically resulting from melanoma. Topline results are, GEP test identified 71% of early stage melanoma tumors that recurred, 70% of those that metastasized distantly, and 80% of those that died from melanoma and using Cox multivariate analysis, GEP test was shown to be a significant predictor of both recurrence.
Castle Biosciences Announces Clinical Results of Melanoma Gene Expression Test in 334-Patient Performance Cohort Study at ASCO 2016
Jun 6 16
Castle Biosciences Inc. announced the results from a study evaluating the performance of its gene expression profile (GEP) test, DecisionDx®-Melanoma, in 334 new melanoma patients. The data confirmed the positive results from two previously published multicenter clinical validation studies demonstrating the test’s ability to identify patients’ risk of melanoma recurrence in the 5 years following diagnosis. The data were presented in a poster session at the 2016 American Society of Clinical Oncology Annual Meeting in Chicago, IL. A second, independent, prospective study of DecisionDx-Melanoma was also presented further confirming the results of the three prior multicenter studies. The data show that GEP classification is significantly associated with early recurrence in patients diagnosed with melanoma. With a median follow-up time of 18 months, the study found a Negative Predictive Value of 98% for disease-free survival. To date, all Stage III patients with a Class 1 result are recurrence free. The DecisionDx-Melanoma test correctly identified 16 of 18 patients who had recurrence events as high-risk (Class 2). Overall the high-risk Class 2 group had a 38% recurrence rate. Patients who were both high-risk Class 2 and Stage III had a 77% recurrence rate compared to 43% with Stage III status alone.
Castle Biosciences, Inc. Announces Appointment of Bernhard E. Spiess as Chief Operating Officer
May 9 16
Castle Biosciences Inc. announced the appointment of Bernhard E. Spiess to the newly created role of Chief Operating Officer. Bernhard comes to Castle Biosciences with over 35 years of clinical diagnostics experience, most recently serving as Vice President of Product Management for both Clinical Chemistry and Infectious Diseases at Beckman Coulter.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|